- Conditions
- Pulmonary Disease, Chronic Obstructive, Asthma, Adverse Effect of Beta-adrenoreceptor Antagonists
- Interventions
- Metoprolol succinate ER, Carvedilol
- Drug
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 964
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Spirometry, ACOS clinical questionnaire
- Procedure · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 12
- States / cities
- Newport Beach, California • Upland, California • Sunset, Louisiana + 9 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- HEPA portable air filter, Sham Control/Active Comparator
- Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
- Interventions
- Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
- Other · Drug
- Lead sponsor
- D. Walter Wray
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2030
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Self-Management Support, COPD Education
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Obstructive Pulmonary Disease, Physical Activity
- Interventions
- Activity monitor/smartphone health coaching
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 22
- States / cities
- Riverside, California • San Diego, California • Wheat Ridge, Colorado + 18 more
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease
- Interventions
- Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 19 Years to 64 Years
- Enrollment
- 12,255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Video Telehealth Pulmonary Rehabilitation
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Iowa City, Iowa + 12 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Not listed
- Lead sponsor
- LASARRUS Clinic and Research Center
- Industry
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Salisbury, Maryland
- Conditions
- Chronic Obstructive Pulmonary Disease, Emphysema, Pulmonary Rehabilitation
- Interventions
- Home-base Pulmonary Rehab with Health Coaching
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg, GW642444 25mcg, GW642444 50mcg, placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 49
- States / cities
- Florence, Alabama • Jasper, Alabama • Montgomery, Alabama + 45 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 8
- States / cities
- Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Interventions
- Salmeterol or Salmeterol/Fluticasone
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- COPD, COPD Exacerbation
- Interventions
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3,406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 276
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Foley, Alabama + 178 more
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
- Interventions
- Steen Solution™, Conventional Lung Transplant
- Device · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 5
- States / cities
- Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- COPD
- Interventions
- Formoterol Fumarate
- Drug
- Lead sponsor
- Dey
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 52
- States / cities
- Jasper, Alabama • Phoenix, Arizona • Buena Park, California + 47 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Proactive Outreach, No Proactive Outreach
- Other
- Lead sponsor
- Harvard Medical School (HMS and HSDM)
- Other
- Eligibility
- Not listed
- Enrollment
- 19,113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg, BD MDI 320 μg, FF MDI 9.6 μg
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Rolling Hills Estates, California • Clearwater, Florida • Panama City, Florida + 14 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BEA 2180 BR, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 83 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 23 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- short chain fatty acid tracers
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 45 Years to 100 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Chronic Obstructive Airway Disease
- Interventions
- Bi-level positive airway pressure (BPAP), Oxygen, CPAP
- Device · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts